Multiple Sclerosis

CTAF, Midwest CEPAC

Multiple sclerosis (MS) is a chronic, immune-mediated inflammatory demyelinating disease of the central nervous system (CNS).

2019 Review: Secondary Progressive MS

Intervention of Interest: Siponimod (Novartis)

2017 Review: Relapsing-Remitting MS and Primary Progressive MS

Interventions of Interest:

Injectable Agents

  • Daclizumab (Zinbryta®, Biogen/AbbVie)
  • Glatiramer acetate (Copaxone®, Teva)
  • Glatiramer acetate (Glatopa®, Sandoz (Novartis))
  • Interferon beta-1a (Avonex®, Biogen)
  • Interferon beta-1b (Betaseron®, Bayer)
  • Interferon beta-1b (Extavia®, Novartis)
  • Interferon beta-1a (Rebif®, EMD Serono)
  • Peginterferon beta-1a (Plegridy®, Biogen)

Oral Agents

  • Dimethyl fumarate (Tecfidera®, Biogen)
  • Fingolimod (Gilenya®, Novartis)
  • Teriflunomide (Aubagio®, Sanofi-Genzyme)

Infused Agents

  • Alemtuzumab (Lemtrada®, Sanofi-Genzyme)
  • Natalizumab (Tysabri®, Biogen)
  • Ocrelizumab (Ocrevus®, Roche/Genentech)
  • Rituximab (Rituxan®, Roche/Genentech)

ASSOCIATED MEETING & MATERIALS

Midwest CEPAC
May 23, 2019 9am-5pm CT

Hyatt Regency O’Hare
9300 Bryn Mawr Avenue
Rosemont, IL 60018

The Midwest CEPAC will convene to review ICER's assessment of siponimod (Novartis) for secondary progressive multiple sclerosis.

Key Dates

Associated Materials

10/10/2018 – 10/30/2018
Open Input Period

10/31/2018

10/31/2018

10/31/2018 – 11/20/2018
Public Comments

11/29/2018
Revised Scoping Document

01/14/2019
Research Protocol

03/14/2019
Draft Evidence Report

03/14/2019
Draft Voting Questions

03/14/2019 – 04/10/2019
Public Comments

05/02/2019
Evidence Report

05/02/2019
Revised Voting Questions

05/02/2019
Response to Comments

05/23/2019
Meeting Agenda

05/23/2019
Evidence Presentation

06/20/2019
Final Evidence Report and Meeting Summary

06/20/2019
Report-at-a-Glance


ASSOCIATED MEETING & MATERIALS

CTAF
February 16, 2017 9:30AM-4:30PM (PT)

Preservation Park
1233 Preservation Park Way
Oakland, CA 94612

The California Technology Assessment Forum convened to discuss ICER's report on treatments for Multiple Sclerosis.

Key Dates

Associated Materials

07/01/2016

07/18/2016

07/22/2016
Revised Scoping Document NOTE: Contains information only on RRMS.

09/06/2016

09/16/2016

10/07/2016

10/07/2016

11/22/2016

11/22/2016

11/22/2016 – 12/21/2016

Public comments on the Draft Evidence Report.


01/26/2017

01/26/2017

01/26/2017

02/16/2017

Please note updated meeting start time. Meeting will begin at 9:30AM PT.